Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive three (3) additional shares for each share held on such date.

18/11/2021

2021-1131 – Consolidation - Algernon Pharmaceuticals Inc. (AGN)

Le 18 novembre/November 2021

Algernon Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every one hundred (100) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 1,678,809 common shares.

The name and symbol will not change.

19/01/2021

2021-0122 - Expiration - Algernon Pharmaceuticals Inc. - Warrants (AGN.WT)

le 19 janvier/January 2021

Further to Bulletin 2020-1240, Algernon Pharmaceuticals Inc. warrants will expire on January 21, 2021.

Settlement Terms: All trades January 19^th and 20^th will settle for cash next day. Trades on January 21 will be for cash same day.

The warrants will be halted at noon and delisted at market close January 21, 2021.

29/12/2020

2020-1240 - Acceleration of Expiry Date – Algernon Pharmaceuticals Inc. - Warrants - AGN.WT

Le 29 décembre/December 2020

14/02/2019

2019-0226 – Changement de nom et de symbole - Breathtec Biomedical Inc. (BTH)

Le 14 février/February 2019

Breathtec Biomedical Inc. (BTH) has announced a name and symbol change to Algernon Pharmaceuticals Inc. (AGN).

Shares will begin trading under the new name and symbol on February 19, 2019.

16/10/2018

2018-1021 – Consolidation - Breathtec BioMedical Inc. (BTH)

Le 16 octobre/October 2018

Breathtec BioMedical Inc. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post-consolidation share for each two (2) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 28,682,012.

The shares will begin trading on a consolidated basis and with a new CUSIP number on October 17, 2018.

The name and symbol will not change.

Dépôts CSE

Fichier	Type	Date
Algernon Annual MD&A	MD & A (Discussion et analyse de la direction)	23/12/2024
Algernon- Annual Financial Statements	États financiers annuels vérifiés	23/12/2024
Algernon Pharmaceuticals - Monthly Progress Report	Rapport d'activité mensuel	17/12/2024
Algernon Monthly Progress Report	Rapport d'activité mensuel	06/11/2024
Notice of Amendment of Warrant Terms	Avis de modification des délais	04/11/2024
Algernon - Sep 2024 Form 7 - Monthly Progress Report	Rapport d'activité mensuel	04/10/2024
Algernon - Aug 2024 Form 7 - Monthly Progress Report	Rapport d'activité mensuel	10/09/2024
Algernon Pharmaceuticals - Form 6 Certificate of Compliance	Certificat de conformité	20/08/2024
Algernon Pharmaceuticals - Form 9 Notice of Proposed Issuance of Securities	Émission proposée des titres cotés	20/08/2024

1
2
3
4
5
6
7
8
9
…
suivant ›
dernier »

Vous êtes ici